Vemedia Revenue and Competitors

Claim your profile

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Vemedia's estimated annual revenue is currently $41.6M per year.(i)
  • Vemedia's estimated revenue per employee is $201,000

Employee Data

  • Vemedia has 207 Employees.(i)
  • Vemedia grew their employee count by -7% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$24.7M123-25%N/AN/A
#2
$4.6M23N/A$114.3MN/A
#3
$33.8M168-11%$204.6MN/A
#4
$21.1M105-7%N/AN/A
#5
$10.5M52-7%N/AN/A
#6
$90.9M400-8%$508.6MN/A
#7
$7.2M36-5%N/AN/A
#8
$113.4M564-9%N/AN/A
#9
$28.9M1440%N/AN/A
#10
$13.5M67-3%N/AN/A

Vemedia BV in Diemen produceert en distribueert al meer dan 70 jaar medische spécialités, farmaceutische producten en voedingssupplementen. Wij zijn een groeiend farmaceutisch bedrijf met gezamenlijk meer dan 150 medewerkers.

keywords:N/A

N/A

Total Funding

207

Number of Employees

$41.6M

Revenue (est)

-7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Vemedia News

2022-04-17 - La Asociación para el Autocuidado de la Salud renueva su Consejo Directivo

... Perrigo, Procter&Gamble Health, Reckitt Benckiser Healthcare, Sanofi, Upsa, Uriach Consumer Healthcare, Vemedia, Viatris y Zambon.

2019-09-12 - Beauty Supplements Market 2019-2028: Consumption Growth Rate, Market Drivers, Opportunities and Import-Export Ratio

... Lifes2good Holdings Limited, Murad UK Ltd, Vitabiotics Ltd, Reserveage LLC, Amway Corporation, BeautyScoop, Vemedia Pharma N.V..

2019-06-14 - Cooper-Vemedia Strengthens In Europe With Diepharmex ...

Switzerland's Laboratoires Diepharmex has been snapped up by Cooper-Vemedia, the pan-European consumer healthcare group backed by ...

2018-04-15 - France's Sanofi sells 12 brands to Charterhouse's Cooper-Vemedia

PA) has agreed to sell a portfolio of 12 pharmaceutical brands to Charterhouse Capital Partners' Cooper-Vemedia drugs manufacturing arm for ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$32.3M2070%$72M
#2
$28.9M207-5%$59.7M
#3
$51.7M2072%N/A
#4
$36.4M207105%N/A
#5
N/A2073%N/A